Team:Penn/LightActivatedOverview

From 2012.igem.org

(Difference between revisions)
Line 16: Line 16:
<div class="bigbox">
<div class="bigbox">
-
These targeting mechanisms are imperfect on their own because they also target healthy tissue. Furthermore, the majority of therapies employ no targeting mechanisms at all (e.g. pharmacologic therapies).
+
<b><div class="name" align="center">YF1/FixJ Characterization</div></b>
-
Even when diseases are clearly localized in specific areas and specific cells (such as cancer), current therapies such as chemotherapy attack the entire body and result in significant adverse effects. Patients who undergo chemotherapy suffer significant damage to fast-dividing cells throughout the entire body, which can result in immune system depression, hair loss, pain, and organ damage.
+
<br>
 +
<p style="color:black;text-indent:30px;">After reading many papers to select an appropriate light-sensing system to use, we selected the YF1/FixJ blue light system. We had also considered the red light sensor Cph8 but ultimately decided on YF1/FixJ because of its high on/off ratio of gene expression and also because of its availability to us (we were fortunate enough to come across the YF1/FixJ system in the form of the pDawn plasmid from the Moglich lab in Germany).</p>
</div>
</div>
</body>
</body>
</html>
</html>

Revision as of 22:56, 26 October 2012

Penn 2012 iGEM Wiki

Image Map

Light-Activated Gene Expression

YF1/FixJ Characterization

After reading many papers to select an appropriate light-sensing system to use, we selected the YF1/FixJ blue light system. We had also considered the red light sensor Cph8 but ultimately decided on YF1/FixJ because of its high on/off ratio of gene expression and also because of its availability to us (we were fortunate enough to come across the YF1/FixJ system in the form of the pDawn plasmid from the Moglich lab in Germany).

Retrieved from "http://2012.igem.org/Team:Penn/LightActivatedOverview"